Optimizing PCSK9 Inhibitors and Analyzing Plaque Reduction Data

Author(s):

Pam Taub, MD, FACC, FASPC,Michael Koren, MD, FACC

Michael Blaha, MD, discusses the efficacy and safety of novel targeted therapies for lowering LDL cholesterol and emphasizes the importance of long-term data in building patient confidence in this new treatment option.

EP: 1.Overview of Low-Density Lipoprotein Cholesterol Management

EP: 2.Stricter LDL-C Targets: Explaining Goalpost Changes to Patients

EP: 3.Ongoing Lp(a) Trials and Clinical Approaches to Treatment

EP: 4.Innovations in Small Interfering RNA (siRNA) Therapy

Now Viewing

Optimizing PCSK9 Inhibitors and Analyzing Plaque Reduction Data

EP: 1.Overview of Low-Density Lipoprotein Cholesterol Management

EP: 2.Stricter LDL-C Targets: Explaining Goalpost Changes to Patients

EP: 3.Ongoing Lp(a) Trials and Clinical Approaches to Treatment

EP: 4.Innovations in Small Interfering RNA (siRNA) Therapy

EP: 5.Optimizing PCSK9 Inhibitors and Analyzing Plaque Reduction Data

EP: 6.Evaluating Safety of Novel LDL Management Mechanism

EP: 7.Examining Results from VICTORION-INITIATE Trial

EP: 8.Other Notable Emerging Lipid-Lowering Treatments

EP: 9.REDUCE-IT Trial and Triglyceride-Lowering Agents

EP: 10.Diabetes, GLP-1, and Lipid Reduction

EP: 11.Medication Adherence in Patients with High LDL Cholesterol

EP: 12.Overcoming Prior Authorization Barriers in LDL Cholesterol Therapies

EP: 13.Cardiometabolic Medicine: Seeing the Patient as a Whole